10-Q: Sunshine Biopharma Q2 2026: Revenue Dip, R&D Advances

Sunshine Biopharma Inc. reported a decrease in revenue for Q2 2026 compared to the prior year, alongside continued net losses, but highlighted progress in its proprietary drug development pipeline and a strengthened cash position.

Summary

• Sunshine Biopharma Inc. reported revenue of $9.26 million for the three months ended June 30, 2026, a 1.6% decrease from $9.41 million in the same period of 2025.
• For the six months ended June 30, 2026, revenue was $17.35 million, down 5.2% from $18.31 million in the prior year.
• The company experienced an increase in cost of sales, leading to a gross profit decrease of 27.3% for the quarter and 25.1% for the six-month period.
• Net loss for the three months ended June 30, 2026, was $1.56 million ($1.15 per share), an improvement from a net loss of $1.77 million ($3.94 per share) in Q2 2025.
• For the six months ended June 30, 2026, the net loss was $2.81 million ($2.95 per share), an improvement from a net loss of $2.95 million ($8.19 per share) in the same period of 2025.
• Cash and cash equivalents increased to $13.75 million as of June 30, 2026, from $9.12 million at the end of 2025.
• The company has two proprietary drug candidates in development: K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections.
• A legal dispute with former employee Malek Chamoun was settled for $1.06 million USD, paid on August 10, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to declining revenues, increased cost of sales, and continued net losses, despite positive developments in R&D and cash position.

Positives

• Cash and cash equivalents increased significantly to $13,748,301 as of June 30, 2026, up from $9,123,308 at the end of 2025.
• Net loss for the three months ended June 30, 2026, improved to $1,564,048 from $1,770,834 in the prior year's quarter.
• Basic loss per common share improved to $(1.15) for the three months ended June 30, 2026, from $(3.94) in the prior year's quarter.
• Basic loss per common share improved to $(2.95) for the six months ended June 30, 2026, from $(8.19) in the prior year's period.
• The company has advanced its proprietary drug development programs, with K1.1 mRNA showing effectiveness in reducing liver cancer tumors in xenograft mice and SBFM-PL4 receiving patent protection.
• The company has 22 additional generic drugs in its pipeline, with 12 anticipated for launch during the remainder of 2026.
• The company entered into an At-The-Market (ATM) Issuance Sales Agreement to potentially raise up to $4,000,000.

Negatives

• Revenue decreased by 1.6% to $9,263,687 for the three months ended June 30, 2026, compared to $9,410,230 for the same period in 2025.
• Revenue decreased by 5.2% to $17,352,452 for the six months ended June 30, 2026, compared to $18,311,571 for the same period in 2025.
• Cost of sales increased as a percentage of revenue, leading to a decrease in gross profit margin from 36.4% to 26.2% for the quarter and from 66.4% to 73.4% for the six-month period.
• Gross profit decreased by $996,184 to $2,426,682 for the three months ended June 30, 2026, compared to $3,422,866 in the prior year.
• Gross profit decreased by $1,545,620 to $4,607,672 for the six months ended June 30, 2026, compared to $6,153,292 in the prior year.
• The company incurred a net loss of $1,564,048 for the three months ended June 30, 2026, and $2,807,917 for the six months ended June 30, 2026.
• Inventory decreased to $12,121,796 from $13,472,025, with an increased allowance for obsolete inventory.
• The company anticipates needing to raise additional capital in the future, with no committed sources of capital.

Risks

• Generic drug prices are highly dependent on government policies in Canada, which may change over time.
• The company is not subject to material customer concentration risks, but provincial governments in Canada reimburse patients for prescription drug expenditures to varying degrees.
• The company has recorded valuation allowances against all of its deferred tax assets and expects to maintain these until there is sufficient evidence that future earnings can be achieved, which is uncertain.
• Additional capital may not be available on terms acceptable to the company, or at all.
• The company's proprietary drug development programs are subject to the inherent risks and uncertainties of drug development, including the possibility of failure to demonstrate safety and efficacy.
• The company's ability to successfully commercialize its proprietary drug candidates is subject to regulatory approvals and market acceptance.
• The termination of distribution agreements effective December 31, 2025, has impacted revenue.
• The company is subject to risks associated with international operations and currency fluctuations.

Future Outlook

The company estimates its existing cash on hand, combined with cash generated from sales, will be sufficient to fund operations for the next 27 months. However, it anticipates the need to raise additional capital in the future for expansion of its generic pharmaceuticals sales operations and further research and development, with no assurance of availability on acceptable terms.

Management Comments

• The Company operates the two subsidiaries as a single business segment.
• The Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces.
• The Company is currently generating revenue of approximately $9 million per quarter and incurring a quarterly deficit of approximately $1.5 million.
• Our attention is currently focused on increasing sales and streamlining operations to reduce expenses.

Industry Context

StockSavvy.ai notes that Sunshine Biopharma operates in the competitive Canadian generic drug market, valued at $11.2 billion annually. The company's strategy involves in-licensing, cross-licensing, and distribution agreements, alongside proprietary drug development in oncology and antivirals. Recent government policy changes in Canada regarding drug reimbursement programs and the federal government's entry into the program are significant factors influencing the market.

Comparison to Industry Standards

• The Canadian generic drug market is valued at approximately $11.2 billion annually (IMARC Group).
• The company has 60 generic prescription drugs on the market in Canada, with 22 additional drugs in the pipeline, aiming to strengthen its presence in this market.
• The development of proprietary drugs like K1.1 mRNA and SBFM-PL4 aligns with industry trends in oncology and antiviral research, particularly in the post-COVID-19 era.
• The company's R&D efforts, including publications in the Journal of Medicinal Chemistry, reflect industry standards for scientific validation and disclosure.

Legal Proceedings

• A legal dispute with Mr. Malek Chamoun, former president of Nora Pharma, was settled for $1,058,565 USD, paid on August 10, 2026.

Related Party Transactions

• During the three months ended June 30, 2026, $232,000 of officer compensation was paid to Advanomics Corporation, a company controlled by the CEO.

Stakeholder Impact

• Shareholders may be impacted by the continued net losses and the need for future capital raises, although improved loss per share and increased cash position are positive signs.
• Customers (pharmacies in Canada) will continue to have access to a portfolio of 60 generic drugs, with potential for new additions.
• Suppliers may be affected by changes in inventory levels and cost of sales.
• Creditors may be impacted by the company's ongoing need for capital and its ability to service debt, though current liquidity appears strong.

Next Steps

• Continue to focus on increasing sales and streamlining operations to reduce expenses.
• Launch 12 additional generic drugs during the remainder of 2026.
• Continue development of proprietary drug candidates K1.1 mRNA and SBFM-PL4.
• Potentially raise additional capital through the ATM offering or other means.
• Confirm results from additional xenograft experiments for K1.1 mRNA.
• Continue research and development for SBFM-PL4, including potential clinical trials.
• Monitor and adapt to changes in Canadian government drug pricing policies.

Key Dates

Recommendation

The company shows signs of operational improvement with reduced net loss per share and a stronger cash position. However, declining revenues, increased cost of sales, and the continued need for future capital raises present significant headwinds. The progress in R&D is promising but long-term and uncertain. Therefore, a 'hold' recommendation is appropriate pending clearer signs of revenue growth and profitability.

Keywords

pharmaceutical, generic drugs, drug development, oncology, antiviral, mRNA, liver cancer, SARS Coronavirus